AIM ImmunoTech

AIM ImmunoTech Acquisitions (Net)

The Acquisitions (Net) of AIM ImmunoTech (AIM) as of Oct 18, 2026 is 4.72 M USD. In the previous year, Acquisitions (Net) was -247,000.00 USD — a change of -2,012.55% (higher).

Acquisitions (Net)

4.72 MUSD

YoY

-2,012.55%

Last updated:

Acquisitions (Net) of AIM ImmunoTech is 2024 4.72 M USD. Acquisitions (Net) of AIM ImmunoTech was 2023 -247,000.00 USD. It decreases by -2,012.55% higher compared to the previous year.

The AIM ImmunoTech Acquisitions (Net) history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Acquisitions (Net)
Date
Acquisitions (Net)
Jan 1, 2017
2.80 M USD
Jan 1, 2018
219,000.00 USD
Jan 1, 2019
-5.78 M USD
Jan 1, 2020
-8.57 M USD
Jan 1, 2021
2,000.00 USD
Jan 1, 2022
11.26 M USD
Jan 1, 2023
-247,000.00 USD
Jan 1, 2024
4.72 M USD
The AIM ImmunoTech Acquisitions (Net) history
YEARAcquisitions (Net)YoY
4.72 MUSD-2,012.55%
-247,000.00USD-102.19%
11.26 MUSD+562,850.00%
2,000.00USD-100.02%
-8.57 MUSD+48.20%
-5.78 MUSD-2,740.18%
219,000.00USD-92.18%
2.80 MUSD-16.94%
3.37 MUSD-50.75%
6.84 MUSD+107.58%
3.30 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AIM ImmunoTech Stock analysis

What does AIM ImmunoTech do? AIM ImmunoTech Inc is a biotechnology company based in Ocala, Florida, operating within the health care sector. The company focuses on the clinical development of drug therapies utilizing natural immune system enhancing technologies for treating viral and immune-based disorders. It employs 31 full-time staff members. AIM ImmunoTech's primary products include Alferon N Injection, approved for intralesional treatment of refractory or recurring external genital warts in patients over 18, and Ampligen, which is under clinical development for Chronic Fatigue Syndrome (CFS). The company also develops Alferon LDO, a low-dose oral liquid formulation of natural alpha interferon. AIM ImmunoTech went public on July 12, 1996, with its ticker symbol AIM and ISIN US00901B3033. Its website is hemispherx.net. The company's operations are centered around research and development activities related to Ampligen and other drugs in development, alongside sales and marketing of Alferon. The firm's activities are primarily directed toward addressing chronic viral and immune-related conditions through innovative therapeutic approaches. AIM ImmunoTech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AIM ImmunoTech stock

Acquisitions (Net) of AIM ImmunoTech is 4.72 M USD in 2024.

Acquisitions (Net) of AIM ImmunoTech changed from -247,000.00 USD to 4.72 M USD, representing a -2,012.55% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Acquisitions (Net) AIM ImmunoTech since 2006 – with annual values, charts, and detailed analysis.

Net acquisitions represent the cash spent on acquiring other businesses, net of divestitures. Large acquisitions can transform a company's growth trajectory.

Acquisitions (Net)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Acquisitions (Net)'s AIM ImmunoTech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — AIM ImmunoTech

All Key Metrics — AIM ImmunoTech